新型三氨酸衍生物具有选择性为c-Jun N-终端激酶 (JNK) 3抑制剂
Igor A Schepetkin1, Oleksander S Karpenko2, Anastasia R Kovrizhina3
1Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
Molecules (Basel, Switzerland)
|June 28, 2023
概括
研究人员开发了新型的三素-6-oxime类似物作为选择性c-Jun N-终端激酶3 (JNK3) 抑制剂. 这些化合物显示出治疗炎症性疾病和神经退行性疾病 (如阿尔茨海默氏症) 的潜力.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 包括JNK1-3在内的c-Jun N-终端酶 (JNK) 家族调节关键细胞过程.
- 新出现的证据将JNK3与神经退行性疾病 (阿尔茨海默氏症,帕金森症) 和癌症联系起来.
- 选择性JNK3抑制是一种治疗标.
研究的目的:
- 合成和评估针对选择性JNK3抑制的新型三素-6-oxime类似物.
- 为了确定具有潜在抗炎和神经保护性质的化合物.
主要方法:
- 合成了26种新的三丁-6-氧胺类同类物.
- 对JNK1-3结合亲和力 (Kd) 和细胞炎症反应抑制的评估.
- 由LPS诱导的NF-κB/AP-1活性和IL-6产生的测定.
- 对c-Jun酸化的西部斑点分析.
- 对JNK3结合相互作用的分子建模.
主要成果:
- 化合物4d和4e对JNK3比JNK1和JNK2具有很高的选择性.
- 这些化合物抑制了LPS诱导的NF-κB/AP-1活性和低微分子范围的IL-6产生.
- 化合物4d,4e和4h降低了LPS诱导的c-Jun酸化,证实了JNK抑制.
- 分子建模支持JNK3催化部位内的结合相互作用.
结论:
- 新型的三素-6-氧胺类比体现了对JNK3.3的显著选择性.
- 这些化合物有望成为潜在的治疗剂,用于炎症和神经退行性疾病.
- 含的异环系统为开发JNK3选择性药物提供了支架.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Eukaryotic Transcription Inhibitors
9.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K


